

Niti Goel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/416071/publications.pdf>

Version: 2024-02-01

83
papers

2,802
citations

218381

26
h-index

189595

50
g-index

89
all docs

89
docs citations

89
times ranked

2746
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 805-811.	0.5	290
2	Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. <i>Arthritis and Rheumatism</i> , 1998, 41, 1173-1180.	6.7	202
3	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.5	194
4	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. <i>Nature Reviews Rheumatology</i> , 2022, 18, 465-479.	3.5	182
5	Pulmonary involvement in systemic sclerosis: Associations with genetic, serologic, sociodemographic, and behavioral factors. <i>Arthritis and Rheumatism</i> , 2007, 57, 318-326.	6.7	161
6	Certolizumab Pegol. <i>MAbs</i> , 2010, 2, 137-147.	2.6	151
7	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. <i>Rheumatology</i> , 2012, 51, 2204-2214.	0.9	115
8	Mechanical sensation and pain thresholds in patients with chronic arthropathies. <i>Journal of Pain</i> , 2003, 4, 203-211.	0.7	106
9	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	1.0	93
10	Familial antiphospholipid antibody syndrome: Criteria for disease and evidence for autosomal dominant inheritance. <i>Arthritis and Rheumatism</i> , 1999, 42, 318-327.	6.7	68
11	Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. <i>Rheumatology</i> , 2012, 51, 1226-1234.	0.9	66
12	Lack of correlation between serum soluble fas/APO-1 levels and autoimmune disease. <i>Arthritis and Rheumatism</i> , 1995, 38, 1738-1743.	6.7	62
13	The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 855-861.	0.5	61
14	Systemic lupus erythematosus in three ethnic groups: IV. Factors associated with self-reported functional outcome in a large cohort study. <i>Arthritis and Rheumatism</i> , 1999, 12, 256-266.	6.7	51
15	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	1.6	50
16	Fracture Reduction Affects Medicare Economics (FRAME): Impact of increased osteoporosis diagnosis and treatment. <i>Osteoporosis International</i> , 2005, 16, 1545-1557.	1.3	45
17	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	1.0	43
18	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	1.0	42

#	ARTICLE	IF	CITATIONS
19	Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 324-341.	0.8	40
20	Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. <i>Rheumatology</i> , 2012, 51, 1628-1638.	0.9	38
21	Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1713-1718.	0.5	36
22	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	1.0	36
23	Development of a Disease Activity and Responder Index for Psoriatic Arthritis – Report of the Psoriatic Arthritis Module at OMERACT 11. <i>Journal of Rheumatology</i> , 2014, 41, 782-791.	1.0	34
24	Enhanced Patient Involvement and the Need to Revise the Core Set – Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , 2015, 42, 2198-2203.	1.0	34
25	Biosimilars in rheumatology: understanding the rigor of their development. <i>Rheumatology</i> , 2017, 56, 187-197.	0.9	30
26	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110579.	1.2	30
27	Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. <i>Osteoporosis International</i> , 2008, 19, 1247-1250.	1.3	26
28	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 965-969.	1.0	24
29	Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 370-384.	0.8	22
30	Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures. <i>Journal of Rheumatology</i> , 2015, 42, 2448-2459.	1.0	21
31	Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. <i>Journal of Rheumatology</i> , 2016, 43, 203-207.	1.0	20
32	Comparison of an Enzyme Immunoassay to an Indirect Fluorescent Immunoassay for the Detection of Antinuclear Antibodies. <i>American Journal of Clinical Pathology</i> , 1999, 111, 503-506.	0.4	17
33	Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective. <i>Journal of Rheumatology</i> , 2015, 42, 1971-1975.	1.0	15
34	Validating Rheumatoid Arthritis Remission Using the Patients'™ Perspective: Results from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1889-1893.	1.0	15
35	Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00380.	1.1	15
36	Perceived Functioning Has Ethnic-specific Associations in Systemic Sclerosis: Another Dimension of Personalized Medicine. <i>Journal of Rheumatology</i> , 2009, 36, 2724-2732.	1.0	14

#	ARTICLE	IF	CITATIONS
37	Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: An analysis of individual patient-level data. <i>Arthritis and Rheumatism</i> , 2011, 63, 2203-2208.	6.7	14
38	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 95, 33-37.	1.0	14
39	Patient Participation in Psoriasis and Psoriatic Arthritis Outcome Research: A Report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1206-1211.	1.0	13
40	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. <i>Current Medical Research and Opinion</i> , 2011, 27, 315-325.	0.9	12
41	Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group. <i>Journal of Rheumatology</i> , 2017, 44, 1727-1733.	1.0	12
42	Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. <i>Journal of Rheumatology</i> , 2017, 44, 1894-1898.	1.0	12
43	Antiphospholipid Antibody Syndrome: Current Concepts. <i>Hospital Practice (1995)</i> , 1998, 33, 129-149.	0.5	11
44	Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 1916-1919.	1.0	11
45	The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). <i>Osteoporosis International</i> , 2010, 21, 713-722.	1.3	10
46	Conducting research in psoriatic arthritis: the emerging role of patient research partners. <i>Rheumatology</i> , 2020, 59, i47-i55.	0.9	10
47	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	1.0	10
48	Building Bridges between Researchers and Patient Research Partners: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015, 42, 1021-1026.	1.0	9
49	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1108-1112.	1.6	8
50	Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda. <i>Journal of Rheumatology</i> , 2015, 42, 1934-1942.	1.0	7
51	Tackling Patient Centricity: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 703-705.	1.0	7
52	Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 1164-1167.	1.0	7
53	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , 2019, 95, 54-57.	1.0	7
54	GRAPPA 2019 Project Report. <i>Journal of Rheumatology</i> , 2020, 96, 53-57.	1.0	7

#	ARTICLE	IF	CITATIONS
55	Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015, 42, 1048-1051.	1.0	6
56	Letâ€™s Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 970-973.	1.0	6
57	Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Preâ€Specified Analysis of Two Phase III Trials. <i>Arthritis Care and Research</i> , 2016, 68, 299-307.	1.5	6
58	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1173-1178.	1.0	6
59	Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1158-1181.	1.6	6
60	Outcomes Reported in Prospective Longâ€Term Observational Studies and Registries of Patients With Rheumatoid Arthritis Worldwide: An Outcome Measures in Rheumatology Systematic Review. <i>Arthritis Care and Research</i> , 2021, 73, 649-657.	1.5	6
61	Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis. <i>Rheumatology and Therapy</i> , 2021, 8, 327-346.	1.1	6
62	Primary Care House Staff Attitudes Toward Osteoporosis Management. <i>Southern Medical Journal</i> , 2006, 99, 461-466.	0.3	6
63	The effects of cultural background on patient-perceived impact of psoriatic arthritis - a qualitative study conducted in Brazil and France. <i>Advances in Rheumatology</i> , 2018, 58, 33.	0.8	5
64	Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 58-66.	1.0	5
65	OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1117-1124.	1.6	4
66	Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1113-1116.	1.6	4
67	The Patient Research Partner Network Matures: A Report from the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 52-53.	1.0	4
68	Pericardial Effusion and Cardiomyopathy Following Arthritis with Parvovirus B19 Infection: Response to Intravenous Immunoglobulin. <i>Journal of Clinical Rheumatology</i> , 2001, 7, 346-349.	0.5	3
69	Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1547-1551.	1.0	3
70	Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 607-617.	1.6	3
71	Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 1732-1736.	0.9	2
72	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2021, , jrheum.201679.	1.0	2

#	ARTICLE	IF	CITATIONS
73	Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 367-386.	1.6	2
74	Enhancing patient research partner engagement: Research in psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101685.	1.4	2
75	Promoting Diversity, Equity, and Inclusion for Psoriatic Diseases. <i>Journal of Rheumatology</i> , 2022, , jrheum.211330.	1.0	2
76	SAT0395â€¦RESPONSIVENESS AND CLINICAL TRIAL DISCRIMINATION OF SWOLLEN AND TENDER JOINT COUNTS FOR THE MEASUREMENT OF MSK DISEASE ACTIVITY IN PSORIATIC ARTHRITIS. , 2019, , .		1
77	FRI0196â€¦TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL. , 2019, , .		1
78	Systemic lupus erythematosus in three ethnic groups: IV. Factors associated with self-reported functional outcome in a large cohort study. , 1999, 12, 256.		1
79	Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2022, , jrheum.211322.	1.0	1
80	Patient perspectives on long-term outcomes in rheumatoid arthritis. A qualitative study from the OMERACT patient outcomes in longitudinal studies working group. <i>Seminars in Arthritis and Rheumatism</i> , 2023, 58, 152028.	1.6	1
81	Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials. <i>Trials</i> , 2015, 16, .	0.7	0
82	Recent Advances in Understanding of the Genetics of Antiphospholipid Syndrome. , 2017, , 53-75.		0
83	Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , 2022, , jrheum.211317.	1.0	0